Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 2:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Solid Tumors (Phase 1) Clear all
Completed Phase 1 Interventional

Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment

NCT00610948
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
panitumumab, everolimus, fluorouracil, leucovorin calcium, oxaliplatin
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Study of Oral PQR309 in Patients With Advanced Solid Tumors

NCT02483858
View directory record Official record
Conditions
Cancer
Interventions
PQR 309
Drug
Lead sponsor
PIQUR Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Phase 1 Study OF CDC-501 in Patients With Solid Tumors

NCT00046735
View directory record Official record
Conditions
Neoplasms
Interventions
Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor

NCT00087217
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
tanespimycin, paclitaxel, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors

NCT00002543
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
gallium nitrate
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Jun 11, 2026, 2:55 AM EDT
Not listed Phase 1Phase 2 Interventional

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

NCT04780217
View directory record Official record
Conditions
Solid Tumor, Hepatocellular Carcinoma, Colorectal Cancer, NSCLC, Ovarian Cancer, Endometrial Cancer
Interventions
T3011
Biological
Lead sponsor
ImmVira Pharma Co. Ltd
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Plantation, Florida • Greenville, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Clofarabine in Adult Patients With Advanced Solid Tumors

NCT00125840
View directory record Official record
Conditions
Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric, Leukemia, Lymphocytic, Acute, Adult, Leukemia, Myelocytic, Acute, Pediatric, Leukemia, Myelocytic, Acute, Adult, Myelodysplastic Syndromes, Adult
Interventions
clofarabine (IV formulation)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Dallas, Texas • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

ABT-751 in Treating Young Patients With Refractory Solid Tumors

NCT00036959
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ABT-751
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
3
States / cities
Chicago, Illinois • Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Jun 11, 2026, 2:55 AM EDT
Suspended Phase 1 Interventional

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

NCT03065062
View directory record Official record
Conditions
Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer, Pancreatic Cancer
Interventions
Palbociclib, Gedatolisib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen

NCT01094288
View directory record Official record
Conditions
Advanced Solid Tumors, Adenocarcinoma of the Prostate
Interventions
Alisertib, Docetaxel
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
4
States / cities
Indianapolis, Indiana • Portland, Oregon • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007

NCT01061788
View directory record Official record
Conditions
Advanced Solid Tumors, Non-small Cell Lung Cancer
Interventions
AMG 479, Everolimus, Panitumumab
Drug
Lead sponsor
Jeffrey Clarke
Other
Eligibility
18 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies

NCT00388427
View directory record Official record
Conditions
Malignant Solid Tumour
Interventions
Dasatinib (BMS-354825), Cetuximab (Erbitux, C225)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Jun 11, 2026, 2:55 AM EDT
Terminated Phase 1 Interventional

A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer

NCT04586270
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
TAS0612
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas

NCT02740270
View directory record Official record
Conditions
Solid Tumors, Lymphomas
Interventions
GWN323, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Jun 11, 2026, 2:55 AM EDT
Not yet recruiting Phase 1 Interventional

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

NCT06748872
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma, Synovial Sarcoma
Interventions
Lymphodepletion, TCR-T cells (MDG1015)
Drug · Biological
Lead sponsor
Medigene AG
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2042
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jun 11, 2026, 2:55 AM EDT
Terminated Phase 1 Interventional

DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

NCT05496595
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
DCBY02
Drug
Lead sponsor
DynamiCure Biotechnology
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Jun 11, 2026, 2:55 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

NCT07460375
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
LCB02A
Drug
Lead sponsor
LigaChem Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Results available

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

NCT02564900
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
DS-8201a (DP1), DS-8201a (DP2), DS-8201a (DP)
Drug
Lead sponsor
Daiichi Sankyo Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
8
States / cities
San Diego, California • Jacksonville, Florida • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2024 · Synced Jun 11, 2026, 2:55 AM EDT
Terminated Phase 1 Interventional

A Study in Subjects With Advanced Solid Tumors

NCT04156100
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
AGEN1223, AGEN1223 and balstilimab
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas

NCT02076451
View directory record Official record
Conditions
Advanced Solid Tumor, Lymphoma
Interventions
DS-8273a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer

NCT01661972
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Capecitabine and aflibercept
Drug
Lead sponsor
John Strickler, M.D.
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Durham, North Carolina • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

SNX-5422 to Treat Solid Tumor Cancers and Lymphomas

NCT00644072
View directory record Official record
Conditions
Lymphoma, Neoplasms
Interventions
SNX-5422
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors

NCT00253565
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
capecitabine, imatinib mesylate
Drug
Lead sponsor
Herbert Hurwitz
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2013 · Synced Jun 11, 2026, 2:55 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

NCT05839600
View directory record Official record
Conditions
Solid Tumors
Interventions
BI 1821736
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
New Haven, Connecticut • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 11, 2026, 2:55 AM EDT